These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36677583)

  • 1. Identifying Dopamine D3 Receptor Ligands through Virtual Screening and Exploring the Binding Modes of Hit Compounds.
    Jin H; Wu C; Su R; Sun T; Li X; Guo C
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D3R Grand Challenge 4: ligand similarity and MM-GBSA-based pose prediction and affinity ranking for BACE-1 inhibitors.
    Sasmal S; El Khoury L; Mobley DL
    J Comput Aided Mol Des; 2020 Feb; 34(2):163-177. PubMed ID: 31781990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity and activation of dopamine D3R from molecular dynamics.
    Feng Z; Hou T; Li Y
    J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large scale free energy calculations for blind predictions of protein-ligand binding: the D3R Grand Challenge 2015.
    Deng N; Flynn WF; Xia J; Vijayan RS; Zhang B; He P; Mentes A; Gallicchio E; Levy RM
    J Comput Aided Mol Des; 2016 Sep; 30(9):743-751. PubMed ID: 27562018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of Ligands for PET with the Dopamine D3 Receptor: In Silico and In Vitro Methods.
    Hsieh CJ; Riad A; Lee JY; Sahlholm K; Xu K; Luedtke RR; Mach RH
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33918451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening.
    Lee JH; Cho SJ; Kim MH
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30257450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.
    Athanasiou C; Vasilakaki S; Dellis D; Cournia Z
    J Comput Aided Mol Des; 2018 Jan; 32(1):21-44. PubMed ID: 29119352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
    Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH
    Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations.
    Misini Ignjatović M; Caldararu O; Dong G; Muñoz-Gutierrez C; Adasme-Carreño F; Ryde U
    J Comput Aided Mol Des; 2016 Sep; 30(9):707-730. PubMed ID: 27565797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shape similarity guided pose prediction: lessons from D3R Grand Challenge 3.
    Kumar A; Zhang KYJ
    J Comput Aided Mol Des; 2019 Jan; 33(1):47-59. PubMed ID: 30084081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulation of d-Benzedrine transmitting through molecular channels within D
    Xie W; Wang M; Li A; Xu SC
    J Biomol Struct Dyn; 2017 Jun; 35(8):1672-1684. PubMed ID: 27191827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of shape similarity based pose prediction method in D3R Grand Challenge 2015.
    Kumar A; Zhang KY
    J Comput Aided Mol Des; 2016 Sep; 30(9):685-693. PubMed ID: 27484214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using novel click chemistry algorithm to design D3R inhibitors as blood-brain barrier permeants.
    Kovalenko AA; Porozov YB; Skorb EV; Shityakov S
    Future Med Chem; 2023 Jun; 15(11):923-935. PubMed ID: 37466055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Protein-Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations.
    Clark AJ; Tiwary P; Borrelli K; Feng S; Miller EB; Abel R; Friesner RA; Berne BJ
    J Chem Theory Comput; 2016 Jun; 12(6):2990-8. PubMed ID: 27145262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculate protein-ligand binding affinities with the extended linear interaction energy method: application on the Cathepsin S set in the D3R Grand Challenge 3.
    He X; Man VH; Ji B; Xie XQ; Wang J
    J Comput Aided Mol Des; 2019 Jan; 33(1):105-117. PubMed ID: 30218199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.